Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Esperion Therapeutics

U.S. FDA Approves Broad New Labels for Esperion’s NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use
From Esperion Therapeutics
Via Business Wire
Tickers ESPR
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.